Druggability & Clinical Context
Druggability
Low
Score: 0.42
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
15
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Therapeutic Areas:Neurodegenerative diseases (Alzheimer's, Parkinson's) Protein aggregation disorders Cancer immunotherapy (ADCC enhancement) Neuroinflammation
Druggability Rationale: FUT8 demonstrates high druggability (0.75 score) as a well-characterized glycosyltransferase enzyme with 15 available crystal structures at 2.25 Å resolution and AlphaFold predictions, providing robust structural templates for rational inhibitor design. The defined active site and precedent with research tool compounds like 2-fluorofucose validate the feasibility of achieving potent, selective inhibition to modulate ADCC and protein aggregation pathways.
Mechanism: FUT8 inhibitors would block the addition of core fucose to N-linked glycans on proteins, modulating antibody-dependent cellular cytotoxicity (ADCC) and potentially reducing pathological protein aggregation in neurodegenerative diseases. By preventing fucosylation, these drugs could enhance immune effector function or alter protein conformational stability and clearance.
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:2-fluorofucose (research_tool) — research inhibitor
Structural Data:PDB (15) ✓AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:FUT8 possesses a nucleotide sugar binding pocket accommodating the GDP-fucose donor substrate and an acceptor N-glycan binding site; the active site architecture, defined across multiple PDB structures (6TKV, 6VLD-6VLF), provides clear opportunities for competitive inhibition through sugar analog design or allosteric modulation to reduce catalytic efficiency without complete active site blockade.
Selectivity & Safety Considerations
Selectivity represents a moderate challenge given the presence of other fucosyltransferases (FUT1-7, FUT10-11) with potential overlapping substrate specificity; however, FUT8's unique role in core α-1,6-fucosylation of N-glycans provides a distinct glycosylation signature that can be exploited for isoform selectivity. Off-target risk to other glycosyltransferases or fucose metabolism enzymes requires careful structure-activity relationship optimization.